Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04870372
Status:
COMPLETED
Last Update Posted:
2021-05-07
First Post:
2020-01-15
Brief Title:
Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinsons Disease
Sponsor:
Second Affiliated Hospital of Soochow University
Organization:
Second Affiliated Hospital of Soochow University
Study Overview
Official Title:
A Multi-center Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center open-label single-arm 8-week investigation of Selegiline for treatment of EDS in PD patients
Detailed Description:
This is a multi-center open-label single-arm 8-week investigation of Selegiline Subjects who have a diagnosis of PD based on UK brain bank criteria with ESS 7 will be received Selegiline as an adjunctive therapy or monotherapy This study will assess the impact of Selegiline treatment on the severity of sleep disturbances among PD patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None